147 related articles for article (PubMed ID: 27506606)
1. Impact of Expression of Vimentin and Axl in Breast Cancer.
Tanaka K; Tokunaga E; Inoue Y; Yamashita N; Saeki H; Okano S; Kitao H; Oki E; Oda Y; Maehara Y
Clin Breast Cancer; 2016 Dec; 16(6):520-526.e2. PubMed ID: 27506606
[TBL] [Abstract][Full Text] [Related]
2. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S
Breast Cancer Res Treat; 2016 Jan; 155(2):235-51. PubMed ID: 26759246
[TBL] [Abstract][Full Text] [Related]
3. Axl receptor tyrosine kinase expression in breast cancer.
D'Alfonso TM; Hannah J; Chen Z; Liu Y; Zhou P; Shin SJ
J Clin Pathol; 2014 Aug; 67(8):690-6. PubMed ID: 24904064
[TBL] [Abstract][Full Text] [Related]
4. Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer.
Nalwoga H; Ahmed L; Arnes JB; Wabinga H; Akslen LA
PLoS One; 2016; 11(1):e0146823. PubMed ID: 26760782
[TBL] [Abstract][Full Text] [Related]
5. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
Seike M; Kim CH; Zou F; Noro R; Chiba M; Ishikawa A; Κunugi S; Kubota K; Gemma A
Oncol Rep; 2017 Jun; 37(6):3261-3269. PubMed ID: 28440492
[TBL] [Abstract][Full Text] [Related]
6. Axl Is a Potential Cancer Prognostic Marker for the Migration and Invasion of Nasopharyngeal Carcinoma.
Jiang C; Zhou L; Wang H; Zhang Q; Xu Y
Adv Clin Exp Med; 2016; 25(3):531-7. PubMed ID: 27629742
[TBL] [Abstract][Full Text] [Related]
7. Axl is a prognostic marker in oral squamous cell carcinoma.
Lee CH; Yen CY; Liu SY; Chen CK; Chiang CF; Shiah SG; Chen PH; Shieh YS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S500-8. PubMed ID: 21842265
[TBL] [Abstract][Full Text] [Related]
8. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
[TBL] [Abstract][Full Text] [Related]
9. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.
Vuoriluoto K; Haugen H; Kiviluoto S; Mpindi JP; Nevo J; Gjerdrum C; Tiron C; Lorens JB; Ivaska J
Oncogene; 2011 Mar; 30(12):1436-48. PubMed ID: 21057535
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells.
Yue CH; Liu LC; Kao ES; Lin H; Hsu LS; Hsu CW; Lin YY; Lin YS; Liu JY; Lee CJ
Mol Med Rep; 2016 Aug; 14(2):1636-42. PubMed ID: 27357025
[TBL] [Abstract][Full Text] [Related]
12. Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.
Lozneanu L; Pinciroli P; Ciobanu DA; Carcangiu ML; Canevari S; Tomassetti A; Căruntu ID
Anticancer Res; 2016 Aug; 36(8):4155-63. PubMed ID: 27466525
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor immunoexpression in triple-negative breast cancers: is it a prognostic factor?
Zaborowski M; Pearson A; Sioson L; Gill AJ; Ahadi MS
Pathology; 2019 Apr; 51(3):327-329. PubMed ID: 30846226
[No Abstract] [Full Text] [Related]
14. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
Mitra D; Bhattacharyya S; Alam N; Sen S; Mitra S; Mandal S; Vignesh S; Majumder B; Murmu N
Breast Cancer Res Treat; 2020 Jan; 179(2):359-370. PubMed ID: 31686261
[TBL] [Abstract][Full Text] [Related]
16. Nestin: predicting specific survival factors for breast cancer.
Gao N; Xu H; Liu C; Xu H; Chen G; Wang X; Li Y; Wang Y
Tumour Biol; 2014 Mar; 35(3):1751-5. PubMed ID: 24443256
[TBL] [Abstract][Full Text] [Related]
17. P-cadherin and vimentin are useful basal markers in breast cancers.
Tsang JY; Au SK; Ni YB; Shao MM; Siu WM; Hui SW; Chan SK; Chan KW; Kwok YK; Chan KF; Tse GM
Hum Pathol; 2013 Dec; 44(12):2782-91. PubMed ID: 24139214
[TBL] [Abstract][Full Text] [Related]
18. Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women.
Ahmed L; Nalwoga H; Arnes JB; Wabinga H; Micklem DR; Akslen LA
APMIS; 2015 Aug; 123(8):688-96. PubMed ID: 26011102
[TBL] [Abstract][Full Text] [Related]
19. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast.
Berclaz G; Altermatt HJ; Rohrbach V; Kieffer I; Dreher E; Andres AC
Ann Oncol; 2001 Jun; 12(6):819-24. PubMed ID: 11484958
[TBL] [Abstract][Full Text] [Related]
20. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
Ishikawa M; Sonobe M; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Date H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S467-76. PubMed ID: 23242819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
